K2 Principal Fund’s NRX Pharmaceuticals Warrant NRXPW Stock Holding History

K2 Principal Fund’s Portfolio NRXPW Stock Details NRXPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-278,011	Closed	-$72K	–	354
2020 Q3	$72K	Hold	278,011	–	–	0.01%	235
2020 Q2	$125K	Buy	278,011 +56,811	+26%	+$8.56K	0.02%	227
2020 Q1	$14K	Buy	+221,200	New	+$26.7K	﹤0.01%	229
2019 Q4	–	Sell	-101,200	Closed	-$17K	–	337
2019 Q3	$17K	Buy	+101,200	New	+$19.7K	﹤0.01%	299
2019 Q2	–	Sell	-101,200	Closed	-$18K	–	311
2019 Q1	$18K	Buy	+101,200	New	+$25.5K	﹤0.01%	279

Other funds holding NRXPW

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

K2 Principal Fund's NRXPW Position: Q1 2020 in Review

K2 Principal Fund sold out of NRX Pharmaceuticals Warrant (NRXPW) in Q1 2020, closing a stake of 101,200 shares — an estimated $12.2K sold.

K2 Principal Fund first reported a position in NRXPW in Q1 2018 and held it in 6 quarters. The position peaked at $39K in Q4 2018. 17 funds tracked by Wall St. Rank hold NRXPW as of Q1 2020.

K2 Principal Fund reported no remaining NRX Pharmaceuticals Warrant position as of Q1 2020 after selling out during the quarter.
K2 Principal Fund sold 101,200 NRX Pharmaceuticals Warrant shares in Q1 2020, an estimated $12.2K.
K2 Principal Fund first reported a position in NRX Pharmaceuticals Warrant in Q1 2018 and held it in 6 quarters.
K2 Principal Fund's NRX Pharmaceuticals Warrant position peaked at $39K in Q4 2018.
17 funds tracked by Wall St. Rank held NRX Pharmaceuticals Warrant as of Q1 2020.

Based on K2 Principal Fund's 13F filing for Q1 2020, filed 15 May 2020.